Protagonist Therapeutics is a Newark, California clinical-stage biopharmaceutical company that turns peptides - short chains of amino acids long dismissed as too fragile to be drugs - into stable, often orally available medicines. Its proprietary peptide discovery and engineering platform powers a pipeline spanning hematology, inflammation/immunology and metabolic disease, anchored by rusfertide (a hepcidin mimetic for polycythemia vera under FDA Priority Review) and icotrokinra, an oral IL-23 receptor blocker partnered with Johnson & Johnson that reached the U.S. market in 2026. Publicly traded on Nasdaq as PTGX, the company pairs internal discovery with high-value pharma partnerships.
Dinesh V. Patel, Ph.D. is the President and CEO of Protagonist Therapeutics (NASDAQ: PTGX), a Newark, California-based biopharmaceutical company he has led since December 2008. With over 38 years spanning medicinal chemistry, drug discovery, venture capital co-founding, and three CEO stints, Patel has guided Protagonist from a peptide-platform startup to a company with its first FDA-approved drug - ICOTYDE (icotrokinra), approved March 2026 as the world's first targeted oral peptide for moderate-to-severe plaque psoriasis, partnered with Johnson & Johnson.